×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Zagotenemab (LY3303560)
therapeutic
1,408 words
KG: CNS
2026-03-26
kind:therapeutic
section:therapeutics
state:published
Contents
Zagotenemab (LY3303560)
💊
Therapeutic Info
Name
Zagotenemab (LY3303560)
Summary
Page for Zagotenemab (LY3303560) - anti-tau monoclonal antibody for Alzheimer's disease
Key Genes/Proteins
BI-hTFR1
,
BDNF
Related Diseases
MS
Linked Hypotheses
2 hypotheses
Knowledge Graph
Related Hypotheses (7)
Synthetic Biology BBB Endothelial Cell Reprogramming
Score: 0.57
Circadian-Synchronized LRP1 Pathway Activation
Score: 0.53
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
LRP1-Dependent Tau Uptake Disruption
Score: 0.44
Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Score: 0.69
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Show 2 more
Related Analyses (3)
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Related Experiments (7)
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Anti-Tau Immunotherapy Dosing Optimization
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo
clinical · proposed · Score: 0.40
Tau Propagation Causality Test — Does Tau Spread Drive Neuro
clinical · proposed · Score: 0.40
Show 2 more
See Also (15)
Senescent Cell Clearance in Neurodegeneration
mechanism · Pages share 4 hypotheses
RNA-Targeted Therapies in Neurodegeneration
mechanism · Pages share 4 hypotheses
PPAR Signaling Pathway in Neurodegeneration
mechanism · Pages share 4 hypotheses
Neurovascular Unit Dysfunction in Neurodegeneration
mechanism · Pages share 4 hypotheses
Endosomal Sorting Defects in Neurodegeneration
mechanism · Pages share 4 hypotheses
Endosomal-Lysosomal Pathway in Neurodegeneration
mechanism · Pages share 4 hypotheses
Cerebral Amyloid Angiopathy Pathway in Neurodegeneratio
mechanism · Pages share 4 hypotheses
Cerebral Amyloid Angiopathy in Neurodegeneration
mechanism · Pages share 4 hypotheses
Extracellular Vesicle and Tunneling Nanotube-Mediated S
mechanism · Pages share 4 hypotheses
Rotigotine and Rivastigmine Combination Therapy for Alz
clinical · Pages share 4 hypotheses
Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516
clinical · Pages share 4 hypotheses
A Phase 3, Randomised, Double-blinded, Placebo-controll
clinical · Pages share 4 hypotheses
KarXT for Alzheimer's Disease Cognitive Impairment - MI
clinical · Pages share 4 hypotheses
Wnt/β-Catenin Signaling Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses
WNK1 Kinase in Neurodegeneration
mechanism · Pages share 3 hypotheses
Show 10 more
Knowledge Graph (7 edges)
BI-hTFR1
mediates
CNS
JEV
infects
CNS
BDNF
expressed_in
CNS
therapeutic agents
associated_with
CNS
MS
regulates
CNS
MICROGLIA
expressed_in
CNS
DAM
expressed_in
CNS